DRL, Cipla’s healthy outlook offsets Q4 slip, will help retain investor interest

For DRL, the US business failed to generate growth compared to the previous year partly due to high base effect as well as price erosion. India sales grew 15% over the year-ago level, aided by sales from the acquired business of Wockhardt and new product launches.

https://ift.tt/3tSQ8ds